drugset / Trial / NCT00767299

A Study of Arzoxifene to Treat Korean Women With Osteoporosis

NCT00767299

Phase 2 Completed 91 enrolled Eli Lilly and Company
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study is for Korean women who are postmenopausal and also suffer from osteoporosis. The study will test if women who are given 20 mg of arzoxifene once a day for six months have a less severe level of osteoporosis than those women who do not take arzoxifene. All patients will receive 500 mg of elemental calcium and 400 to 600 IU Vitamin D daily starting 4 weeks prior to study drug administration continuing through the 6 months of therapy.

Timeline

Start
2008-12
Primary completion
2009-10
Completion
2009-10

Drugs

EvaluationDrugModalityDoseRoute
Subject arzoxifene Other / unclassified 20 mg Oral

Indications